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Abstract 
Influenza virus infection is diagnosed in most cases using a rapid influenza antigen 
diagnostic test (RIDT). However, false-negative results are a major concern. By contrast, 
the nucleic acid amplification test offers high sensitivity and therefore can aid the 
interpretation of negative RIDT results. In this study, influenza viral loads were 
quantified with quantitative reverse transcription-polymerase chain reaction (qRT-PCR) 
using viral suspensions left over after RIDT, and the performance of both methods was 
evaluated. qRT-PCR detected as few as 103 copies/mL of influenza viruses A and B, 
whereas RIDT showed negative results for viral loads less than 107 and 105 copies/mL 
of influenza viruses A and B, respectively. These results indicate that small quantities of 
the virus that cause false-negative RIDT results can be detected efficiently with 









The rapid influenza antigen diagnostic test (RIDT) using immunochromatography is 
used widely to detect viral antigens. RIDT requires no special skills or instruments and 
has a short turnaround time; therefore, it is a common point-of-care test for the detection 
of influenza virus infections (Welch and Ginocchio, 2010). Although its usual 
specificity exceeds 90%, its analytical sensitivity is variable, ranging from 10% to 80% 
(Chartrand et al., 2012; Uyeki et al., 2009). This variability may be attributable to 
differences in kit contents such as the medium or swab (Hurt et al., 2007; Luinstra et al., 
2011; Smieja et al., 2010), patient age (Hurt et al., 2007; Ruest et al., 2003), the type of 
respiratory specimen (Agoritsas et al., 2006), and the time of sampling from illness 
onset (Ward et al., 2004). In particular, physical factors during sample collection have 
direct effects on the results (Smieja et al., 2010).  
Conversely, the nucleic acid amplification test (NAAT) offers high sensitivity 
and it has therefore been developed for the detection of various viruses (Templeton et al., 
2004). This technique also detects multiple targets in multiple samples (Wu et al., 2008; 
Yang et al., 2010). Despite these advantages, NAAT is not in general use in the clinical 
setting because it is complex and time-consuming. The Centers for Disease Control and 
Prevention (2013) recommend that further influenza testing be considered for patients 
who test negative with RIDT when community influenza activity is high and laboratory 
confirmation of influenza is desirable. However, further testing requires additional 
sample collection. From a pragmatic point of view, NAAT would be most beneficial if it 
were performed with the sample material left over after RIDT. Moreover, technical bias 
from the sample collection process would be eliminated if the same sample was used. In 
the present study, influenza viral loads were quantified using quantitative reverse 
transcription-polymerase chain reaction (qRT-PCR) in viral suspensions left over after 
RIDT, and the performance of both methods was evaluated. 
 
2. Materials and Methods 
2.1. Clinical specimens 
Two hundred fifty-five nasopharyngeal swab specimens were collected from patients at 
Nagasaki University Hospital between December 2012 and March 2013. All clinical 
specimens were examined using a Clearline Influenza A/B (H1N1) 2009 assay (Alere 
Medical, Tokyo, Japan) according to the manufacturer’s instructions. Viral suspension 
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that remained after RIDT was stored at -80°C until RNA extraction.  
 
2.2. Viral RNA preparation 
Viral RNA was extracted directly from a 140-µL viral suspension using a QIAamp Viral 
RNA Mini kit (QIAGEN, Hilden, Germany) and digested with Amplification Grade 
DNase I (Sigma Aldrich, St. Louis, MO, USA) according to the manufacturer’s 
instructions. Subsequently, the viral RNA was diluted with four volumes of RNase-free 
water and used as the template for qRT-PCR. For the positive control, AMPLIRUN 
Influenza A H1, H3, and B RNA controls were purchased from Vircell Microbiologists 
(Granada, Spain). 
 
2.3. Primer and probe design for qRT-PCR 
The primers used for influenza A virus quantification were modified partially from 
those described previously (Centre for Health Protection, 2009; Ward et al., 2004), and 
the probe was selected from the Universal Probe Library (Roche Applied Science, 
Mannheim, Germany). The primers and probes used for influenza A virus subtyping 
(Centre for Health Protection, 2009) and influenza B virus quantification were as 
described previously (van Elden et al., 2001; Wu et al., 2008), with modifications. 
 
2.4. Preparation of viral RNA standards for viral load quantification  
Complementary DNA was synthesized from AMPLIRUN Influenza A H3 and B RNA 
controls using SuperScript III Reverse Transcriptase (Invitrogen, Carlsbad, CA, USA) 
and random primers (Invitrogen). PCR was performed with AmpliTaq Gold (Applied 
Biosystems, Foster City, CA, USA) to amplify a matrix gene of the influenza A virus 
and a hemagglutinin gene of the influenza B virus using primers FLUAM-1F/1R and 
INFB-1/2, respectively (Table 1). The PCR products were isolated and purified using a 
QIAquick PCR purification kit (QIAGEN) before cloning with a TA PCR Cloning kit 
(pTAC-1; Bio Dynamics Laboratory, Tokyo, Japan). Plasmids were recovered using a 
QIAprep Spin Miniprep kit (QIAGEN) and sequenced with a 3130 Genetic Analyzer 
(Applied Biosystems). The plasmid of influenza A was amplified further with PCR 
using primers FLUAM-1R and M13-T7_rev 
(5′-TTCTAATACGACTCACTATAGGGCGGATAACAATTTCACACAG-3′). The PCR 
product was purified with the QIAquick PCR purification kit and used as the template 
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for in vitro transcription. The plasmid of influenza B was digested by the restriction 
enzyme BamHΙ (Takara Bio, Shiga, Japan) and purified using the QIAquick PCR 
purification kit. RNA was synthesized via in vitro transcription using a 
MEGAshortscript T7 kit (Ambion, Austin, TX, USA) and purified using a MEGAclear 
kit (Ambion). Purified RNA was separated via MultiNA capillary electrophoresis 
(Shimadzu, Kyoto, Japan), and a single band was confirmed.  
 
2.5. qRT-PCR 
One-step RT-PCR was performed using LightCycler 480 RNA Master Hydrolysis 
Probes (Roche Applied Science) in 20-µL reaction mixtures containing 5 µL diluted 
viral RNA, 7.3 µL LightCycler 480 RNA Master Hydrolysis Probes (2.7 × conc.), 1.3 
µL Activator, 1 µL Enhancer (20 × conc.), 0.5 µM primer (each), and 0.25 µM probe 
(each). The primers and probes used are shown in Table 1. RT-PCR conditions were 
63°C for 3 min and 95°C for 30 s, followed by 45 cycles of 95°C for 10 s and 58°C for 
30 s. Standard curves were drawn from serial dilutions of viral RNA standards. For 
positive RIDT samples, either the influenza A or the influenza B virus was quantified. 
For negative RIDT samples, the influenza A and B viruses were quantified separately. 
qRT-PCR was performed using both H1 and H3 primers for positive RIDT samples to 
subtype the influenza A virus biplex. For negative RIDT samples, qRT-PCR was 
performed separately for H1 and H3 subtyping because the biplex reaction was found to 
be less sensitive than the monoplex reaction. 
 
3. Results 
3.1. Comparison of RIDT and qRT-PCR results 
RIDT showed a positive result in 34 of 255 samples, which included 31 seasonal 
influenza A and 3 influenza B infections (Fig. 1). Pandemic influenza A 2009 (H1N1) 
was not detected in any sample. qRT-PCR was performed using these 34 positive RIDT 
samples and 77 randomly selected negative RIDT samples obtained from 101 patients. 
The median age of the patients was 42 years (range, 0–92 years). All patients, except 
two, had fever, respiratory symptoms, or both. The median time from illness onset to 
specimen collection was 1 day (range, 0 to >7 days). The two patients without fever and 
respiratory signs lived with persons infected with influenza virus. Viral RNA was 
readily amplified in all of the positive RIDT samples in concordance with the type of 
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influenza virus. For the 77 negative RIDT samples, amplification was observed clearly 
in 22 samples for influenza A, three for influenza B, and one for both influenza types, 
whereas 51 samples lacked amplification for either influenza A or B (Fig. 1).  
 
3.2. Limits of detection of RIDT and qRT-PCR 
Viral copy number was assessed in 34 positive and 26 negative RIDT samples that were 
determined to be positive using qRT-PCR. The quantum of the influenza A viral load 
ranged from 107 to 1011 copies/mL in the positive RIDT samples and 103 to 108 
copies/mL in the negative RIDT samples (Fig. 2). The quantum of the influenza B virus 
ranged from 105 to 109 copies/mL in the positive RIDT samples and 103 to 105 
copies/mL in the negative RIDT samples (see Fig. 2). Accordingly, the limit of detection 
of RIDT was 107 to 108 copies/mL for influenza A and 105 copies/mL for influenza B, 
whereas that of qRT-PCR was 103 copies/mL for both influenza A and B. These 
outcomes indicate that low copy numbers of the viruses that result in negative RIDT 
results can be detected with qRT-PCR.  
 
3.3. Influenza A virus subtyping 
Influenza A subtype was determined using subtype-specific primers and probes for 31 
influenza A samples detected by RIDT and 23 influenza A samples detected by 
qRT-PCR but not RIDT. The 31 samples detected by RIDT were amplified clearly by 
H3 primers. In the 23 samples detected by only qRT-PCR, eight samples were amplified 
by H3 primers and 15 samples were amplified by neither H3 nor H1 primers, perhaps 
due to the low viral copy number. Therefore, all influenza A viruses amplified by 
subtype-specific primers were of the H3 subtype. 
 
3.4. Clinical outcome of patients with false-negative RIDT results 
The clinical outcome of the 24 patients with positive qRT-PCR but negative RIDT 
results was assessed retrospectively. All of the patients except one received no antiviral 
agents, whereas 20 patients were prescribed antibiotics. During antibiotic therapy, a 
patient showed serious influenza symptoms for more than 8 days in the absence of a 
clear diagnosis. Another patient was admitted after antibiotic therapy with a diagnosis of 
pneumonia and was further treated with another antibiotic. Some of the other patients 
received multiple examinations to determine causes for their illness other than influenza 
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virus, but ultimately, the results did not account for their symptoms.  
 
4. Discussion 
Despite inappropriate treatment in patients with positive qRT-PCR results but negative 
RIDT results, all patients who did not receive antivirals recovered eventually from their 
influenza symptoms. However, the illnesses of two patients progressed to pneumonia 
with hypoxia. One developed pneumonia after steroid pulse therapy for myelitis. RIDT 
was performed 4 days after fever onset and gave a negative result, whereas qRT-PCR 
detected 1.3 × 105 copies/mL of influenza A virus in the same specimen. Bronchoscopy 
and blood tests performed to obtain causal information did not result in a definitive 
diagnosis. This patient also presented with encephalopathy, although its relevance to the 
influenza virus was unclear. The other patient developed pneumonia and serious 
hypoxia with pulmonary oedema due to chronic renal failure. RIDT was performed 
once on days 1 and 2 after symptom onset, but the results for both specimens were 
negative, whereas qRT-PCR detected 1.24 × 105 copies/mL of influenza B virus in the 
second specimen. These results indicate that infection with even a small amount of 
influenza virus can have serious outcomes if patients are at risk for complications such 
as immunosuppressive therapy or chronic renal dysfunction. 
 The RIDT results were obtained using one commercial kit in this study. 
However, the stability of viral RNA in the solution included with RIDT kits was 
evaluated with qRT-PCR using two RIDT kits: Clearline Influenza A/B and 
QuickNavi-Flu (Denka Seiken, Niigata, Japan). A clinical viral sample was placed in the 
solution provided by each kit and stored under various conditions to select a kit and 
determine a storage condition for the experiments. The qRT-PCR results showed that 
viral RNA was sufficiently amplified without remarkable degradation when samples 
were stored at -80°C, and no substantial differences were found between the two kits 
(data not shown). These results suggest that the kit used in the experiments was 
representative of other commercially available RIDT kits.  
 The present study provides evidence that influenza infection cannot be ruled 
out by negative RIDT results because the test has low sensitivity. Particularly when 
influenza activity is high, the negative predictive value of RIDT is low, and therefore 
the chance that a negative result is a true negative is also low (Harper et al., 2009). 
Nevertheless, antiviral treatment was not initiated for most patients who tested negative 
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with RIDT but positive with qRT-PCR, indicating that the RIDT results affected clinical 
decision-making to a considerable extent. In other words, most clinicians ruled out 
influenza virus infection based on negative RIDT results despite the high rate of 
false-negative results with RIDT. Such judgments might lead to inappropriate antibiotic 
use, unnecessary examinations, and further viral spread. NAAT can be performed when 
RIDT results are inconsistent with clinical presentation. However, as a general rule, 
NAAT requires additional sample collection. The results of the present study show that 
samples left over after RIDT can be used for NAAT and that even a quantity of virus as 
low as 103 copies/mL can be detected using qRT-PCR without invasive sample 
re-collection. Furthermore, qRT-PCR allows the determination of influenza A subtype. 
Taken together, these results suggest that effective and accurate clinical 
decision-making may be facilitated by the implementation of NAAT using samples left 
over after RIDT. 
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Fig. 1. Sequential results of the rapid influenza antigen diagnostic test (RIDT) and 
quantitative reverse transcription-polymerase chain reaction (qRT-PCR). Influenza A 
and B are highlighted in light and dark grey, respectively. *One sample was positive for 
both influenza A and B. 
Fig. 2. Quantification of influenza viruses A and B with quantitative reverse 
transcription-polymerase chain reaction and the results of the rapid influenza antigen 
diagnostic test (RIDT). Large quantities of virus were detected in 34 samples with 
positive RIDT results, whereas smaller quantities were detected in 26 samples with 




Table 1. Primer and probe sequences 
 Primer and 
probe names 
Oligonucleotide sequence (5′–3′) Reference 
Primers and probe for quantification of the influenza A matrix gene 
 FLUAM-1F AAGACCAATYYTGTCACCTCTGA Centre for Health Protection, 2009; 
Ward et al., 2004, with modifications 
 FLUAM-1R CAAAGCGTCTACGCTGCAGTCC Centre for Health Protection, 2009; 
Ward et al., 2004 
 UPL probe104 FAM-GTGCCCAG-TAMRA Centre for Health Protection, 2009; 
Ward et al., 2004 
Primers and probe for quantification of the influenza B hemagglutinin gene 
 INFB-1 AAATACGGTGGATTAAAYAAAAGCAA van Elden et al., 2001, with 
modifications; Wu et al., 2008  
 INFB-2 CCAGCAATAGCTCCGAAGAAA van Elden et al., 2001; Wu et al., 2008 
 INFB probe Cy5-CACCCATATTGGGCAATTTCCTATGGC
-BHQ3 
van Elden et al., 2001; Wu et al., 2008 
Primers and probe for the influenza A hemagglutinin gene (H1 subtype) 
 H1-247F AACATGTTACCCAGGGCATTTCGC Centre for Health Protection, 2009 
 H1-361R GTGGTTGGGCCATGAGCTTTCTTT Centre for Health Protection, 2009 
 H1-278P Cy5-GAGGAACTGAGGGAGCAATTGAGTTC
AG-BHQ3 
Centre for Health Protection, 2009, 
with modifications 
Primers and probe for the influenza A hemagglutinin gene (H3 subtype) 
 H3-293f F ACCCTCAGTGTGATGGCTTCCAAA Centre for Health Protection, 2009 
 H3-400R TAAGGGAGGCATAATCCGGCACAT Centre for Health Protection, 2009 
 H3-342P HEX-ACGCAGCAAAGCCTACAGCAACTGT
T-BHQ1 
Centre for Health Protection, 2009 
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